Harvard Business Review

SEPTEMBER 12, 2012

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients. Negative results are usually not published at all.

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

JUNE 9, 2017

How the most innovative providers are creating value. In some states, accepting a cup of coffee from a pharmaceutical company must be reported, so “education” over lavish meals or in resort settings has largely receded. Insight Center. The Leading Edge of Health Care. Sponsored by Optum.

Conflict of Interest 14

Conflict of Interest Pharmaceuticals Policies Industry 14

Harvard Business Review

MAY 29, 2013

We share a common belief that innovation comes from the edges," said Luisa Delgado , an SAP HR director, who noted the company valued the ability of many autistic people to "think differently and spark innovation." Ethics Human resources Innovation OCPD' There is a real risk that the cure could be worse than the disease.

Competitive Advantage 11

Competitive Advantage Ethics Human Resources Pharmaceuticals 11

Harvard Business Review

JANUARY 15, 2013

By inextricably linking the two, we confine the practice of real, turbo-charged capitalism to business, and we dangerously limit the capacity of non-business organizations to innovate, fund, and bring to scale the kind of breakthrough ideas that will begin to solve the huge social problems we face today. This we call ethics.

Learning Curve 12

Learning Curve Advertising GDP Pharmaceuticals 12

Harvard Business Review

SEPTEMBER 15, 2014

Consider Ashoka , which provides start-up funding and support for social innovators worldwide. As Linda Hill and her colleagues have described, the company needed expert knowledge as it navigated the technically and ethically challenging waters of pharmaceutical development and marketing.

Gilbert 12

Gilbert Participative Cooper Network Economy 12

Harvard Business Review

JULY 14, 2017

A recent survey on easing racial tensions at work by the Center for Talent Innovation found that “The workplace is one of few settings where we commonly interact across racial and ethnic lines.” Make work safe for discussion and conflict. Businesses should work hard to maintain this reputation.

Diversity 13

Diversity Politics Survey Incubator 13

Harvard Business Review

OCTOBER 13, 2014

When pharmaceutical companies conduct clinical trials to test the safety and efficacy of their drugs as part of the process for obtaining regulatory approval, some patients receive the drug and others some standard existing treatment or a sugar pill (placebo). The change is a success, right? Maybe or maybe not.

Flextime 14

Flextime Call Center Human Resources CRM 14

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

NOVEMBER 28, 2017

Even in one of the most market-oriented societies in human history, it appears very difficult to make most people appreciate that ethical and profitable business practices do not fundamentally conflict. Doing so entails operating more efficiently or innovating to create products that consumers value more. Our research.

Company 10

Company Short-term Long-term Price 10

Harvard Business Review

MAY 18, 2015

Research in the area of behavioral business ethics has demonstrated that most of the initial ethical transgressions in business go unnoticed, even for those committing the transgression. We rationalize our bad behaviors to such an extent that we do not realize we are crossing ethical boundaries until it is too late.

Compliance 8

Compliance Company Self-aware Ethics 8

Marshall Goldsmith

FEBRUARY 8, 2018

Co-founder of Rose Park Advisors—Disruptive Innovation Fund. A leading thinker on strategy and breakthrough innovation. Formerly a leader in the automotive, retail, restaurant, media innovation and consulting industries. Leads Tuck’s incredibly innovative coaching program. Leading innovator in HR for over 25 years.

Executive Coaching 70

Executive Coaching CEO Banking Magazine 70

Harvard Business Review

FEBRUARY 3, 2017

The business model of research-based pharmaceutical companies is under significant pressure. However, it also reflects stronger pressures to lower medicine costs in traditional pharmaceutical markets. citizens than pharmaceuticals (the sector’s worst showing in 16 years). citizens have a positive opinion of big pharma.

Reputation 8

Reputation Pharmaceuticals Price Business Model 8